Details for Patent: 10,434,103
✉ Email this page to a colleague
Which drugs does patent 10,434,103 protect, and when does it expire?
Patent 10,434,103 protects LYTGOBI and is included in one NDA.
This patent has twenty-three patent family members in nineteen countries.
Drugs Protected by US Patent 10,434,103
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Taiho Oncology | LYTGOBI | futibatinib | TABLET;ORAL | 214801-001 | Sep 30, 2022 | RX | Yes | Yes | 10,434,103 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,434,103
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2016240841 | ⤷ Subscribe | |||
Brazil | 112017019809 | ⤷ Subscribe | |||
Canada | 2980888 | ⤷ Subscribe | |||
China | 107406455 | ⤷ Subscribe | |||
China | 111393446 | ⤷ Subscribe | |||
Denmark | 3279202 | ⤷ Subscribe | |||
European Patent Office | 3279202 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |